Limula
Limula SA is a Swiss medtech company that automates cell and gene therapy manufacturing via LimONE, a closed single-vessel platform combining bioreactor and centrifuge. It serves biotech developers, hospitals, and CDMOs producing CAR-T, HSC, NK, and TIL therapies, and began generating first commercial revenues in early 2026.
- Company typePrivate
- Founded2020
- HeadquartersLa Tour-de-peilz, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Limula does
Limula SA is a Swiss cell and gene therapy manufacturing technology company founded in 2020 and headquartered at Biopôle in Lausanne, with operations spanning Switzerland, Italy, Portugal, and France. The company develops automated, closed-system hardware that combines a bioreactor and a centrifuge inside a single vessel, eliminating the cell transfers between devices that characterize conventional cell therapy workflows. This "one-pot" architecture sequences incubation, centrifugation, and volume management without open human intervention, supporting scalable volumes from 2 mL to 400 mL and diverse modalities including CAR-T, hematopoietic stem cells, NK cells, and TILs. A U.S. patent covering the integration method was granted in May 2025.
The commercial product portfolio consists of LimGROW, a research-tier platform for process development, and LimONE, a clinical/commercial platform unveiled in March 2025 for GMP-grade end-to-end cell therapy manufacturing. Both products share the same core consumable, eliminating re-engineering when customers transition from research to clinical production. Limula's revenue model centers on device sales paired with single-use consumables, supplemented by a Technology Access Program that places functional prototypes with selected biotech, hospital, and CDMO partners. Pricing is not publicly disclosed; first commercial revenues were generated in early 2026 from engagements with eight biotech companies and clinical centers, following the company's transition from development to commercial phase under incoming CEO Thomas Eaton.
Limula targets three primary customer segments: biotech and biopharma developers of autologous and allogeneic cell therapies, hospitals and clinical cell therapy centers performing stem cell transplantation and point-of-care manufacturing, and contract development and manufacturing organizations (CDMOs). Named end-users and partners include San Raffaele Telethon Institute for Gene Therapy (Italy), Institut Paoli-Calmettes (France, 150+ annual transplants), Stemmatters (Portugal), University of Geneva, University of Fribourg, and Bracco Imaging. The company is venture-backed (CHF 6.2M seed led by LifeX Ventures, May 2024) and supported by substantial non-dilutive funding including EIC Pathfinder (€4.7M), Innosuisse (CHF 2.5M Accelerator), and FIT grants, with headcount stated at 1-10 employees as of the most recent disclosure.
Limula firmographics
Firmographics- Name
- Limula
- Legal name
- Limula SA
- Website
- https://limula.ch
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Limula SA is a Swiss medtech company that automates cell and gene therapy manufacturing via LimONE, a closed single-vessel platform combining bioreactor and centrifuge. It serves biotech developers, hospitals, and CDMOs producing CAR-T, HSC, NK, and TIL therapies, and began generating first commercial revenues in early 2026.
- Ownership category
- akta.pro rank
Limula industry classification
Industry- Product category
- Cell Therapy Manufacturing Equipment
- NAICS
- Medical Equipment and Supplies Manufacturing (33911)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)
- akta.pro secondary industry
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Limula is headquartered
LocationHeadquarters
- HQ city
- La Tour-de-peilz
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Limula business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales
Revenue model
- Automated cell therapy manufacturing devices and consumables: Limula sells its LimONE automated manufacturing platform and associated single-use consumables to cell therapy developers, CDMOs, and hospitals. The platform is designed for GMP-compliant clinical-grade production.
- Technology access and pilot programs: Early access program providing selected partners access to the technology for pilot testing and process development, generating first commercial revenues starting early 2026 through engagements with eight biotech companies and clinical centers.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Limula product offering
Product offeringCore offering
Limula provides a unified platform for cell and gene therapy manufacturing that combines a bioreactor and a centrifuge into a single closed vessel, enabling both cell incubation and in-situ centrifugation without cell transfers. Its two main products, LimGROW (for process development and research) and LimONE (for clinical-grade commercial manufacturing), use the same core technology and consumable so protocols transfer seamlessly from R&D to GMP production of CAR-T, hematopoietic stem cells (HSCs), NK cells, and other ATMPs.
Product overview
Limula provides a unified platform for cell and gene therapy manufacturing across scales. The company offers two main products: LimGROW and LimONE. LimGROW is a research-appropriate implementation designed for process development and optimization, while LimONE is the commercial-scale platform for clinical-grade production. Both products share the same core technology that combines a bioreactor and centrifuge into a single vessel, enabling seamless technology transfer from research to commercial production without process changes.
Differentiator
Problem solved
Functional benefit
Brands
- LimGROW: Research-appropriate implementation of Limula's technology for process development, empowering users to develop, optimise, and derisk process steps that require incubation.
- LimONE
Products and services
- LimGROW LimGROW is a research-appropriate implementation of Limula's bioreactor-centrifuge technology, designed for process development. It enables cell therapy developers to develop, optimize, and derisk incubation-requiring process steps before implementing full automation on the clinical platform.
- LimONE LimONE is Limula's clinical-grade manufacturing platform that combines a mechatronic hardware device, single-use consumable, and software suite to deliver fully automated, closed, end-to-end production of CAR-T, gene-edited HSCs, and other cell therapies. It supports scalable volumes from 2 mL to 400 mL and was used to complete a 7-day fully automated CAR-T run with over 40-fold cell expansion.
Quantifiable outcome
- Over 40-fold cell expansion achieved in first fully automated CAR-T production run, outperforming current gold-standard solutions
- +5 more outcomes
Companies that use Limula
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
Limula technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Limula partnerships and signals
Strategic signalPartnerships
13 partnerships are on record, tiered core and minor.
- Bracco ImagingcoreGlobal pharmaceutical company in diagnostic imaging, expanding into cell therapy manufacturing. Innosuisse-funded R&D project with Limula and University of Fribourg to combine lipid-based microbubble technology with Limula's automated processing for bead-free cell selection and activation. Goal is to reduce costs and improve treatment quality.
- University of Fribourg (Prof. Nicola Vannini)coreInnosuisse-funded collaboration with Bracco and Limula to develop automated cell selection alternative using microbubbles. Prof. Vannini contributes expertise in T-cell physiology and metabolism to evaluate impact on cell product fitness.
- Institut Paoli-Calmettes (IPC)coreLeading cancer comprehensive centre in Marseille, France, performing over 150 stem cell transplants annually. Collaboration to adopt LimONE for autologous HSC transplantation, focusing on cryoprotectant removal and cell debris washing. Dr. Boris Calmel, Head of Manufacturing at IPC Cell Therapy Center, provides external validation of technology differentiation.
- San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)coreWorld-recognized centre of excellence in Milan for research and clinical translation of cell and gene therapy. Partnership to explore novel bioreactor for expansion of hematopoietic stem cells, building on SR-Tiget's expertise in HSC-based gene therapy (developed Strimvelis and Libmeldy). Initiated under EIC Pathfinder Cell and Gene Therapy Sub Portfolio.
- CSEMcoreSwiss technology innovation center supported Limula in moving technology from prototype to pre-industrial stage. Innosuisse-funded project to find most suitable manufacturing process for large-scale industrial production while preserving functionalities. Resulted in pre-industrial solution used by Limula and partners for cell therapy production testing.
- University of Geneva (Prof. Denis Migliorini)coreInnosuisse-funded project to develop non-viral gene transfer technology for next-generation CAR-T cell therapies. Prof. Migliorini leads Brain Tumour and Immune Cell Engineering Group (BTICE) at AGORA Cancer Research Centre. Published peer-reviewed article on magnetic bead-sensitized optoporation for mRNA CAR-T in 2025.
- StemmatterscorePortuguese CDMO providing expertise in Quality by Design of cell therapy process development and cGMP manufacturing. Partner in Eurostars grant (EUR 1.14M) and EIC PAT4CGT project. Received first LimONE device installation in June 2025 for training and GMP operations.
- CeidoscoreSwiss company developing C-NETICS automated system for continuously monitoring cell density and viability. Partner in Eurostars grant to integrate on-line and real-time cell analytics module into Limula's bioreactor technology for end-to-end CAR-T production.
- Da Vinci LabscoreDeeptech accelerator based in France coordinating the PAT4CGT consortium. Provides research and innovation support services. Synthetic Biology Practice Leader Nadège Grabowski contributed to EIC project evaluation.
- Jobst TechnologiescoreSpin-off of University of Freiburg, Germany, bringing expertise in miniature biosensors and micro control systems for PAT4CGT project.
- Technische Universität Wien (Prof. Christoph Herwig)minorBioprocess Technology research group contributes to development of digital twins and predictive algorithms for PAT4CGT project.
- ExotheraminorBelgian company offering development and manufacturing services for viral vectors, providing end-user inputs and in-depth assessment of resulting PAT4CGT solution.
- FjarylminorStockholm-based industrial design firm that partnered with Limula to incorporate input from over 20 academic and industry experts into key design choices for LimONE following in-person feedback sessions in Lausanne.
Scale indicators13 records
Recent moves6 records
Expansion highlights6 records
Limula competitors and assessment
Company assessmentDirect peers
- Cellares: Cellares offers the Cell Shuttle, an automated cell therapy manufacturing platform targeting large-scale GMP production. It competes head-to-head with LimONE for biotech and CDMO accounts and represents one of the best-capitalized automation startups (>$250M raised) pursuing the same end-to-end cell therapy manufacturing vision.
- Cytiva: Cytiva (formerly GE Healthcare Life Sciences, owner of Sepax and Sefia systems) provides automated cell processing platforms widely used in biobanks, transplant centers, and cell therapy manufacturing. Limula's Head of Operations Olivier Waridel previously led Biosafe Group, the Sepax originator, before its acquisition by GE. Sepax is a direct competitor to LimONE's in-situ centrifugation approach.
- Ori Biotech: Ori Biotech's IRO platform is designed to automate and scale cell and gene therapy manufacturing with a closed, GMP-compliant system. It is a direct competitor targeting the same biotech and CDMO customer segments as Limula and offers similar throughput and process-control benefits.
- Miltenyi Biotec: Miltenyi Biotec's Prodigy platform is one of the most widely adopted automated cell therapy manufacturing systems. It directly competes with LimONE in autologous and allogeneic cell processing for CAR-T, HSC, and other cell therapies, and represents the entrenched incumbent Limula must displace in hospital and CDMO accounts.
Broad incumbents
- Lonza: Lonza is a global CDMO and bioprocess technology provider offering the Cocoon platform for automated cell therapy manufacturing. As both a CDMO service provider and equipment supplier, Lonza competes with Limula across both equipment sales and manufacturing services, with significantly greater scale and commercial reach.
- Terumo BCT: Terumo BCT (now part of Terumo) offers the Quantum cell expansion system for cell and gene therapy manufacturing. It serves hospital and biopharma customers with automated, closed cell processing capabilities and competes with Limula in cell therapy manufacturing automation.
- Sartorius: Sartorius provides upstream and downstream bioprocessing equipment and consumables used across cell therapy manufacturing workflows. While not a direct cell therapy platform competitor, Sartorius competes for the same bioprocessing budgets and is increasingly offering integrated cell therapy manufacturing solutions.
- Thermo Fisher Scientific: Thermo Fisher Scientific offers cell therapy manufacturing solutions through its bioproduction and pharma services businesses, including cell processing equipment, consumables, and contract manufacturing services. It competes broadly with Limula across the cell therapy manufacturing value chain and has substantially greater commercial and R&D resources.
Emerging players
- Multiply Labs: Multiply Labs develops robotic cell therapy manufacturing systems that automate the production of cell therapies using industrial robotics. As an early-stage company, it overlaps with Limula in targeting automation of CAR-T and other cell therapy manufacturing for biotech and CDMO customers.
Regional players
- Stemmatters: Stemmatters is a Portuguese CDMO specializing in cell therapy manufacturing that has partnered with Limula in the PAT4CGT consortium and is an early LimONE installation site. While primarily a service provider rather than a direct equipment competitor, Stemmatters represents an important channel and reference customer in the European market.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
Limula social profiles
Digital presenceLimula financial estimates
Financial estimateRevenue estimate
Valuation estimate
Limula leadership team
Management profileNumber of profiles
Profiles11 records
Limula funding detail
Funding detailFunding overview
Funding rounds13 records
Investors15 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Limula M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Limula
What does Limula do?
Limula provides a unified platform for cell and gene therapy manufacturing that combines a bioreactor and a centrifuge into a single closed vessel, enabling both cell incubation and in-situ centrifugation without cell transfers. Its two main products, LimGROW (for process development and research) and LimONE (for clinical-grade commercial manufacturing), use the same core technology and consumable so protocols transfer seamlessly from R&D to GMP production of CAR-T, hematopoietic stem cells (HSCs), NK cells, and other ATMPs.
Is Limula a public or private company?
Limula is a private company. It is classified as venture growth investor backed and is currently operating.
When was Limula founded?
Limula was founded in 2020. It employs 1 to 10 people.
Where is Limula based?
Limula is headquartered in La Tour-de-peilz, Switzerland, in the Europe region.
How does Limula make money?
Two revenue lines are on record. Automated cell therapy manufacturing devices and consumables are the primary driver. The others are technology access and pilot programs.
Who are Limula's main competitors?
Direct peers on record are Cellares, Cytiva, Ori Biotech and Miltenyi Biotec. Broad incumbents are Lonza, Terumo BCT, Sartorius and Thermo Fisher Scientific. Multiply Labs is listed as an emerging player. Stemmatters is listed as a regional player.
Does Limula have an API?
No public API is recorded for Limula.
What industry is Limula in?
Limula's product category is Cell Therapy Manufacturing Equipment. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 33911 and its SIC code is 8731.